Astellas Pharma (Astellas Pharma) YoY EBITDA Growth : -25.57% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Astellas Pharma's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -25.57%.

Astellas Pharma's EBITDA per Share for the three months ended in Dec. 2023 was $0.26.

Astellas Pharma YoY EBITDA Growth Historical Data

The historical data trend for Astellas Pharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma YoY EBITDA Growth Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

YoY EBITDA Growth

Get a 7-Day Free Trial

10.52

6.64

-29.93

0.92

-8.08

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															-27.35	-282.35	-1.38	-59.58	-25.57

Astellas Pharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Astellas Pharma's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

	YoY EBITDA Growth (A: Mar. 2023 )
=	(EBITDA per Share (A: Mar. 2023 )	-	EBITDA per Share (A: Mar. 2022 ))	/	\| EBITDA per Share (A: Mar. 2022 ) \|
=	(1.012	-	1.101)	/	\| 1.101 \|
=	-8.08 %

Astellas Pharma's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(0.259	-	0.348)	/	\| 0.348 \|
=	-25.57 %

Astellas Pharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.